Clinical Trials Logo

Clinical Trial Summary

The investigators propose a pilot feasibility study to determine if exercise delivered by passive electrical muscle stimulation (EMS) in patients with end stage renal disease (ESRD) on hemodialysis improves physical fitness and insulin resistance, outcome markers associated with morbidity and mortality in this population.


Clinical Trial Description

Subjects who enroll and meet the inclusion and none of the exclusion criteria will first undergo baseline testing including recording of demographic, medical, dialysis and exercise history, taking surveys to assess quality of life and overall mood, measurement of vital signs and anthropomorphic measurements (height, weight, thigh circumference), have blood collected to assess insulin resistance and cytokine levels, measurement of distance walked in 6 minutes and testing of thigh muscle strength.

Subjects will then undergo a 1 month observation period to monitor and optimize their dialysis treatment.

After 1 month the subjects will undergo a repeat assessment of all the baseline testing. They will also undergo a standardized exercise stress test and measurement of body fat and lean body mass with a dual-energy x-ray absorptiometry (DXA) scan.

Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator ("EMPI 300PV" or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.

At 2 and 4 months the subjects will undergo again have repeat assessment of the baseline testing as well as undergoing the standardized exercise stress test and a DXA scan.

At 4 months the subjects will all stop the passive exercise training and then will be followed up 1 month later to repeat assessment of all the baseline testing but will not undergoing the standardized exercise stress test and a DXA scan.

For subjects who agree the investigators will also perform a muscle biopsy under local anesthesia before and 4 hours after the first exercise training session and again at 2 and 4 months. This is used to measure messenger RNA response (gene expression testing) to tell what genes are activated during training.

The efficacy of the exercise training will be assessed by change in aerobic capacity measured by maximal oxygen consumption (peak VO2) and quadriceps muscle strength measured

The primary outcome measure will be whether exercise training improves measures of insulin resistance The investigators will also assess whether there is improvement in other inflammatory and oxidative stress cytokines in the blood stream and whether the training improved their physical performance or overall quality of life.

The total duration of the study for any patient is expected to be 6 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03517553
Study type Interventional
Source University of Iowa
Contact
Status Active, not recruiting
Phase N/A
Start date January 1, 2014
Completion date June 1, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05031013 - Trace Elements Concentration in Dialysis
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT01685372 - Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults Phase 2
Active, not recruiting NCT01394770 - Aliskiren or Amlodipine in Hypertensive Hemodialysed Patients Phase 4
Completed NCT00537979 - Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Phase 4
Completed NCT00506441 - A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Phase 3
Completed NCT05415969 - CKD-aP Among Adults on Dialysis in Switzerland
Recruiting NCT04024007 - Determination of Citrate Clearance Used in Regional Anticoagulation of Continuous Venous Hemofiltration Circuits
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Active, not recruiting NCT01693263 - Outcome of BCF Access in Hemodialysis Patients
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Active, not recruiting NCT01065389 - Resistance Training in Intradialysis Patients Phase 2
Completed NCT00544492 - Study of Pain, Anxiety and Complications Related to Cannulation of Arteriovenous (AV) Fistula in Chronic Hemodialysis Patients Phase 4
Completed NCT03910426 - Prognostic Determinants of Survival and Quality of Life in Prevalent End-stage Kidney Disease Patients
Completed NCT04667741 - Post-dialysis Recovery Time and Affecting Factors Between Turkey and Portugal
Completed NCT04565522 - Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers
Completed NCT04655989 - A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System N/A
Completed NCT05125848 - Clinical Evaluation of the CM-1500 During Hemodialysis N/A
Completed NCT04633915 - Antibody Response in Hemodialysis and Non-dialysis Patients Diagnosed With COVID-19.